Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, B-Cell

Explore clinical trials studying Lymphoma, B-Cell. Study availability and eligibility vary by location and protocol.

503 public trials 139 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, B-Cell trial results

Completed

VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma

NCT00085696

Conditions
B-cell Lymphoma, Follicular Lymphoma, Hemic and Lymphatic Diseases, +11 more
Locations
  • UCLA School of Medicine Los Angeles, California, United States
  • Florida Cancer Specialists Fort Myers, Florida, United States
  • Emory University Cancer Institute, Winship Cancer Institute Atlanta, Georgia, United States
  • Georgia Cancer Specialists Marietta, Georgia, United States
View all 13 locations
View Trial Details
Completed

R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas

NCT00558220

Conditions
Diffuse Large B-Cell Lymphoma., Follicular Lymphoma Grade III, Hemic and Lymphatic Diseases, +11 more
Locations
  • University Hospital Brno-Bohunice Brno, Czechia
  • Hospital Chomutov Chomutov, Czechia
  • Hospital České Budějovice České Budějovice, Czechia
  • University Hospital Hradec Králové Hradec Králové, Czechia
View Trial Details
Completed

Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)

NCT00168740

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • City of Hope Natioal Medical Center Duarte, California, United States
  • Scripps Memorial Hospital La Jolla, California, United States
  • UCSD Stem Cell Laboratory La Jolla, California, United States
View all 31 locations
View Trial Details
Active, Not Recruiting

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

NCT05397496

Conditions
B-cell Acute Lymphoblastic Leukemia (B-ALL), B-cell Non-Hodgkin Lymphoma (B-NHL), Burkitt Lymphoma, +20 more
Locations
  • University Of Miami Miami, Florida, United States
  • University of Chicago Medical Center Chicago, Illinois, United States
  • The University of Kansas Clinical Research Ctr Fairway, Kansas, United States
  • Memorial Sloan Kettering Cancer Ctr New York, United States
View all 18 locations
View Trial Details
Active, Not Recruiting

Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

NCT03478514

Conditions
B Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • University of Maryland, Greenebaum Comprehensive Cancer Center Baltimore, Maryland, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • St. Joseph Mercy Hospital Cancer Care Center Ypsilanti, Michigan, United States
View Trial Details
Active, Not Recruiting

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

NCT04884035

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • Local Institution - 162 Birmingham, Alabama, United States
  • Local Institution - 154 Scottsdale, Arizona, United States
  • Local Institution - 169 Duarte, California, United States
  • Local Institution - 160 Jacksonville, Florida, United States
View all 36 locations
View Trial Details

Related conditions